title: Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
abstract: OBJECTIVE
  This study aimed at comparing the efficacy and tolerability of 5 different regimens for Helicobacter pylori eradication in recent years.
  
  
  METHODS
  H. pylori-positive patients with dyspeptic symptoms were included and separated into 5 groups. The 'PAC group' was given pantoprazole, amoxicillin and clarithromycin for 14 days. The 'PAM group' was given pantoprazole, amoxicillin and metronidazole for 14 days. The 'bismuth-containing group' was given pantoprazole, bismuth subsalicylate, tetracycline and metronidazole for 14 days. The 'sequential group' was given pantoprazole and amoxicillin for 5 days, followed by pantoprazole, tetracycline, and metronidazole for the next 5 days. The 'concomitant group' was given pantoprazole, amoxicillin, tetracycline, and metronidazole for 10 days. Eradication was assessed through the urea breath test on 6 weeks after eradication therapy.
  
  
  RESULTS
  The eradication rate of intention-to-treat/per protocol were 42/48.3% in the PAC group, 52/54.2% in the PAM group, 62/77.5% in the bismuth group, 71/80.7% in the sequential group and 72/83.7% in concomitant group. The frequency of mild and moderate side effects was similar between groups.
  
  
  CONCLUSIONS
  The concomitant and sequential therapies are an effective treatment for H. pylori. Bismuth-containing therapy is superior to conventional triple therapies; however, the eradication rate is not satisfactory. In our country, conventional triple therapies are not effective for eradication.
authors.affiliation: Department of Gastroenterology, Konya Education and Research Hospital, Konya, Turkey.
authors.forename: Gokhan
authors.initials: G
authors.lastname: Gungor
authors.forename: Murat
authors.initials: M
authors.lastname: Baglıcakoglu
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Kayacetin
authors.forename: Murat
authors.initials: M
authors.lastname: Biyik
authors.forename: Ramazan
authors.initials: R
authors.lastname: Ucar
authors.forename: Hakan
authors.initials: H
authors.lastname: Goktepe
authors.forename: Huseyin
authors.initials: H
authors.lastname: Ataseven
authors.forename: Ali
authors.initials: A
authors.lastname: Demir
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001729:Bismuth / Q000009:adverse effects / Q000627:therapeutic use*; D001944:Breath Tests; D002985:Clinical Protocols; D060740:Disease Eradication; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077402:Pantoprazole; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use*; D014421:Turkey
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D012459:Salicylates; D008795:Metronidazole; C015715:bismuth subsalicylate; D000077402:Pantoprazole; D001729:Bismuth